by April Breyer Menon | Mar 16, 2020
In the Spring 2020 edition of IAM, Christopher Loh was quoted on what the current wave of biosimilar litigation signals for the future. According to the article, the substantial increase in patent litigation involving biosimilar drugs over the past few years has...
by April Breyer Menon | Mar 12, 2020
Download PDF Download...
by April Breyer Menon | Feb 29, 2020
February was a busy month for the FDA in the field of biosimilars: On February 3, 2020, the FDA and FTC issued a joint statement regarding their enhanced collaboration to support the adoption of biosimilars and interchangeables. On February 3, 2020, the FDA...
by April Breyer Menon | Feb 6, 2020
Download PDF Download...
by April Breyer Menon | Jan 22, 2020
Venable partner Ha Kung Wong spoke at the Specialty Therapies and Biosimilars Conference as part of a panel that discussed biosimilar litigation and patent issues. He focused on the impact of inter partes reviews (IPRs) and post grant reviews (PGRs) on how patents...